News
Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...
3d
MedPage Today on MSNSubcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data
TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...
Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...
A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...
Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...
Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an ...
Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a ...
Erin Kelly is likely going to forget her eight-year-old daughter Evie’s name before her little girl finishes high school.
Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...
6don MSN
Alzheimer’s ‘wonder drug’ slows progression of disease by four years - and could even reverse it
An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers ...
A Harvard team reverses dementia in mice with a metal supplement, after showing that its deficiency drives the disease ...
Lithium could help treat cases of Alzheimer’s disease, a Harvard study suggests. People with the neurodegenerative condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results